Current evidence suggests that most, if not all, GBMs express CXCR4 and CCR5 [27,28,29] and these receptors are related to the survival, invasiveness, proliferation and resistance to the radio- and chemotherapy of glioma tumors [27,28,30,48,49,50]. Here, CXCR4 is linked to central nervous system cancer.